Ziopharm data shows ZIO-101 kills myeloma cells

By Elaine Rigoli

Tampa, Fla., April 5 - Ziopharm Oncology, Inc. announced Wednesday the results of a preclinical study that show ZIO-101, a new organic arsenic drug, kills myeloma cells.

The data, presented during the annual meeting of the American Association of Cancer Research, suggest ZIO-101 might be active in cancers where arsenic trioxide is ineffective or too toxic, according to a news release.

The data suggests that differences in chemical structure of ZIO-101 and arsenic trioxide are reflected in the different sensitivities of human multiple myeloma cell lines. Therefore, cancers resistant to one arsenic may respond to another, officials said.

"We are now enrolling patients with advanced myeloma in a phase 1/2 trial at doses of ZIO-101 much higher than we could safely achieve with arsenic trioxide. We are encouraged by these results, and will further evaluate ZIO-101 as we move forward with our trial," James Berenson of Berenson Oncology said in the release.

Ziopharm is a biopharmaceutical company based in New York.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.